Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.

Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.

Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.

People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.

Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.

Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).

Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.

Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.

Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.

Understanding the interaction between genes and lifestyle factors in response to stress can lead to potential therapeutic interventions for stress-related disorders. This research is crucial for promoting health and well-being.

Professor Divya Mehta works as a Principal Research Fellow at the Stress Genomics Laboratory, in Queensland University of Technology in Australia, specialising in stress genomics and mental health. Her education started in the UK with undergraduate and Masters, followed by her PhD in Germany. 11 years ago Professor Mehta moved to Australia.

Associate Professor Peter Psaltis is an Academic Interventional Cardiologist who holds Level 2 NHMRC Career Development and National Heart Foundation Future Leader Fellowships. He has Faculty positions within the University of Adelaide, Central Adelaide Local Health Network (CALHN) and South Australian Health and Medical Research Institute (SAHMRI). Within SAHMRI, he is the Co-Theme Leader of the Lifelong Health, Program Leader of Heart and Vascular Health and Co-director of the Vascular Research Centre in the Lifelong Health Theme.

Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.

Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.

Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.

His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).


His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.

Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.

The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.

Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.

Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.

The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.